|"Mission: To improve the health and well being of Hispanics. The National Alliance for Hispanic Health is the premier organization focusing on Hispanic Health. Alliance members reach over 12 million Hispanic consumers throughout the U.S. Since 1973 we have grown from a small coalition of visionary mental health providers to a large, dynamic, and strong group of organizations and individuals." (http://www.hispanichealth.org/; accessed 11/23/05) |
When New York State in 2005 tried to adopt a preferred drug list (formulary) for its Medicaid program, Assemblyman Peter M. Rivera, a Bronx Democrat and chairman of the Assembly's Puerto Rican/Hispanic Task Force, helped lead the opposition by distributing a report that claimed Hispanics react differently to drugs and restrictions could force Hispanics to take inappropriate medicines. "While couching its conclusions in sober scientific language, the report was in fact a crucial weapon in the industry's campaign," the New York Times reported. "It was issued by the National Alliance for Hispanic Health, an advocacy group in Washington that is heavily financed by pharmaceutical companies and has a corporate advisory board whose members are mostly pharmaceutical executives, according to the group's records. The alliance worked on the report with the National Pharmaceutical Council, a trade group of major pharmaceutical companies." (Michael Luo, "Drug Costs Run Free Under New York Medicaid," New York Times, Nov. 23, 2005, Pg. 1)
According to the Alliance for Hispanic Health's 2003 Annual Report (available on the group's website, six of nine groups on its Corporate Advisory Board are drug or medical device companies. Members include:
- Pfizer Inc.
- Merck & Co.
- Medtronic Inc.
- Wyeth-Ayerst Global Pharmaceuticals
- Johnson & Johnson
- Eli Lilly and Company